Vitamin B6 is effective therapy for nausea and vomiting of pregnancy: A randomized, double‐blind placebo‐controlled study

Sahakian, Vicken; Rouse, Dwight J.; Sipes, Susan L.; Rose, Nancy B.; Niebyl, Jennifer R.

doi:10.1016/0020-7292(92)90077-v

Cited by 102 publications

(119 citation statements)

References 0 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…Although we could not duplicate their results, others have described oral pyridoxine as effective therapy when given orally. 5 Our past experience as well as others did not mirror that result. 17 Therefore, oral pyridoxine was not used.…”

Section: Significancementioning

confidence: 67%

“…Subjective scores of 1-5 were noted by the patient as follows: much worse (1), worse (2), same (3), better (4), and much better (5). The responses were then divided into two subgroups: those that answered 1-3 (same-worse) and those that answered 4-5 (better).…”

Section: Methodsmentioning

confidence: 99%

“…4 Prochlorperazine, promethazine, metoclopramide, and pyridoxine (vitamin B 6 or B 6 ) are often used as first-line therapy. 5 Newer regimens using ondansetron or steroids are also utilized, either as first-line therapy or more likely after initial therapy failure. The majority of studies tend to focus on the management of hyperemesis gravidarum with little investigation of nausea and vomiting in pregnancy.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of Three Outpatient Regimens in the Management of Nausea and Vomiting in Pregnancy

2003

View full text Add to dashboard Cite

Objective:This study compares pyridoxine-metoclopramide combination therapy to prochlorperazine and promethazine monotherapies in the outpatient treatment of nausea and vomiting in pregnancy. Study Design:In total, 174 first trimester, singleton pregnancies were evaluated for nausea and vomiting. Patients were prospectively randomized into three treatment groups: pyridoxine-metoclopramide, prochlorperazine, or promethazine. Prior to, and on the third day, patients recorded their subjective responses to the given treatment and their number of emesis episodes. The three treatment groups were compared for therapy response. Results:There were no differences in the number of emesis episodes prior to treatment. Both subjective and objective responses to treatment differed among the three groups when comparing the combination therapy to the monotherapies (p<0.05). Conclusion:Combination therapy with pyridoxine and metoclopramide appears to be superior to either monotherapy in the treatment of nausea and vomiting in pregnancy.

show abstract

Section: Significancementioning

confidence: 67%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of Three Outpatient Regimens in the Management of Nausea and Vomiting in Pregnancy

2003

View full text Add to dashboard Cite

show abstract

“…Two controlled trials have shown the efficacy of administering pyridoxine to treat NVP patients. 87,88 The two studies revealed a significant decrease in nausea and the number of vomiting episodes, and that most patients with severe nausea reported considerable improvement in their symptoms (from severe to moderate or mild nausea). Pyridoxine is also safe, inexpensive, and available as an over-thecounter product.…”

Section: Alternative Treatmentsmentioning

confidence: 97%

Nausea and Vomiting of Pregnancy

Kouzi¹

2003

Am J Pharm Educ

View full text Add to dashboard Cite

Nausea and vomiting symptoms affect 70% to 85% of pregnant women during early pregnancy. These symptoms can have a dramatic effect on a woman's family, social, and occupational functioning. Hence, nausea and vomiting of pregnancy is a medical condition that should be taken seriously by health care professionals responsible for providing care to pregnant women. This manuscript reviews the current state of knowledge concerning the etiology, underlying mechanisms, and management of nausea and vomiting associated with pregnancy. An abbreviated version of the material found in this article is presented to second year PharmD students at the University of the Pacific as part of an elective course on evidence-based complementary and alternative therapies.Keywords: nausea and vomiting, pregnancy, drug therapy, complementary and alternative therapies and the fetus. Even when the condition is not so severe, symptoms can cause considerable distress and temporary disability. 3 Nearly 50% of employed women believed their work efficiency was substantially reduced by NVP, and as many as 25% required time off from work. Almost one half of women with NVP said that it had adverse effects on their relationships with their spouse, and 55% of pregnant women with NVP felt depressed. The financial burden of severe NVP on the American health system has been estimated to be about $130 million per year, which is based on an annual average of 39,000 hospital discharges at a mean cost of $3,300 per stay. These figures do not include physician fees, loss of productivity at home or on the job, or the cost for patient treatment.

show abstract

“…It may have intrinsic antiemetic properties and also may be synergistic with the antinauseant property of antihistamines. [3][4][5] DCL has been used since the l950's and is considered to be a safe treatment for nausea and vomiting associated with pregnancy. 6 The international Cochrane collaboration has systematically reviewed randomized trials of DCL, and concluded that it safely provides considerable relief for nausea and vomiting of pregnancy.…”

Section: Conclusion : Le DCL Périopératoire Oral Réduit L'incidence Dmentioning

confidence: 99%

Prophylactic Diclectin® reduces the incidence of postoperative vomiting

Cook

Babineau

Scholes³

et al. 2005

Can J Anesth/J Can Anesth

View full text Add to dashboard Cite

B Ba ac ck kg gr ro ou un nd d: : Diclectin® (DCL) is an effective antiemetic used for relief of nausea and vomiting in pregnancy. It is unknown whether DCL is effective in the prevention of postoperative nausea and vomiting (PONV).M Me et th ho od ds s: : We conducted a randomized, stratified, double-blind placebo-controlled trial to examine the incidence of PONV in women undergoing elective laparoscopic tubal ligation in the day surgery setting. DCL (doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg) was administered orally the night before surgery, the morning of surgery, and upon hospital discharge.Results: We enrolled 146 women in the trial, 127 of whom were included in the effectiveness analysis and 102 of whom were included in the efficacy analysis. We did not detect a difference in the incidence of nausea and vomiting in the first six hours postoperatively after adjusting for additional antiemetics administered. Patients receiving DCL as compared with placebo were significantly less likely to experience vomiting six to 24 hr postoperatively [5/59 (8.5%) vs 14/55 (25.4%), P < 0.017]. Treated patients tended to return to work earlier than those who received placebo (1.74 vs 3.7 days P = NS).C Co on nc cl lu us si io on n: : Perioperative oral DCL reduces the incidence of postoperative vomiting in women undergoing elective laparoscopic tubal ligation, and may accelerate return to work. Contexte : Le Diclectin® (DCL) est un antiémétique efficace contre les nausées et les vomissements pendant la grossesse. On ne sait pas s'il peut prévenir les nausées et vomissements postopératoires (NVPO). Méthode

show abstract

Vitamin B6 is effective therapy for nausea and vomiting of pregnancy: A randomized, double‐blind placebo‐controlled study

Cited by 102 publications

References 0 publications

Comparison of Three Outpatient Regimens in the Management of Nausea and Vomiting in Pregnancy

Comparison of Three Outpatient Regimens in the Management of Nausea and Vomiting in Pregnancy

Nausea and Vomiting of Pregnancy

Prophylactic Diclectin® reduces the incidence of postoperative vomiting

Contact Info

Product

Resources

About